News

 
All News

 

.

TamRx Launches to Develop Pipeline of Immuno-oncology Products for Treatment of Cancers

Published: September 04, 2019

 

New company’s bifunctional technology blocks tumor growth and stimulates the immune system to fight cancer

CLEVELAND, FEBRUARY 7, 2019 — BioMotiv, a drug development accelerator associated with The Harrington Project for Discovery & Development, and researchers from Rutgers, The State University of New Jersey, today announced the formation of a new biotech start-up, TamRx. The new company will focus on the development of a novel family of small molecule inhibitors designed to block tumor growth and stimulate the immune system to fight various forms of cancer.

“The potential held by this novel technology to both block tumor growth and elicit an anti-tumor immune response is very exciting,” said Baiju R. Shah, CEO of BioMotiv. “We look forward to working with Drs. Birge, Welsh, and Peng as they advance their discoveries with the TamRx team.”

Read more